

Key Trends for Active Employees and Early Retirees

Based on Paid Claims Through January 2024 Rolling Year

March 2024




Executive Summary

- Overall allowed PMPY trend rose 7.9% from \$8,856 to \$9,556
- Inpatient allowed medical PMPY decreased by 3.1%, driven by a decrease of 6.8% facility charges
 - Allowed amount PMPY for surgical and maternity admissions decreased by 11.1% and 14.1%, respectively; resulting in a decrease in net pay
 PMPY of 4.4%
- Outpatient medical PMPY increased by 10.3% from \$4,812 to \$5,269
 - Allowed amount PMPY increased the greatest for substance abuse (39.0%); medical specialty medications (23.8%); and physical, occupational, and speech therapies (20.7%), driven by an increase in services per 1,000
 - There was an increase in the number of patients utilizing mental health and substance abuse by 7.9% and 13.8%, respectively
 - Allowed amount per service increased for 14.0% for medical specialty medications; the three most costly were to treat cancer (Keytruda and Neulasta) and multiple sclerosis (Ocrevus)
- Pharmacy payments were driving 27.3% of the cost overall and increased by 12.9% PMPY from the previous rolling year
 - Specialty drugs incurring the largest costs on the pharmacy plan were medications used to treat rheumatoid and psoriatic arthritis and other skin conditions; they were Humira, Stelara, and Dupixent

Overall Trend

Annual Trend


| Aimai ficha | | | |
|---------------------------------------|---------------|---------------|--------|
| | Feb 2022 – | Feb 2023 – | % |
| | Jan 2023 | Jan 2024 | Change |
| Allowed Amount | \$883,629,924 | \$963,503,315 | 9.0% |
| Coordination of Benefits ¹ | \$14,290,560 | \$25,964,494 | 81.7% |
| Out of Pocket | \$44,085,038 | \$48,287,773 | 9.5% |
| Net Payment | \$825,254,326 | \$889,251,048 | 7.8% |
| Members Avg Med or Rx | \$99,781 | \$100,823 | 1.0% |
| Allow Amt PMPY | \$8,856 | \$9,556 | 7.9% |
| Allow Amt PEPY | \$19,515 | \$20,948 | 7.3% |
| Net Pay PMPY | \$8,271 | \$8,820 | 6.6% |
| Net Pay PEPY | \$18,226 | \$19,333 | 6.1% |
| | | | |



3

¹Increase in Coordination of Benefits is largely due to the addition of PrudentRx Claims. Coordination of Benefits for PrudentRx consists of a "residual copay required by the manufacturer or the remaining drug cost after the program benefits are exhausted or unavailable. This amount is billed back to the plan" (CVS Report Definitions, State of DE State Employee Benefits Comm Savings Report). This does not include any savings, which are not included in this report and not included in the overall Allowed Amount.

Overall PMPY Trend




Allowed Amount PMPY Trend

| | Feb 2022 - Jan 2023 | Feb 2023 - Jan 2024 | % Change |
|-------------------|---------------------|---------------------|----------|
| IP Medical | \$1,968 | \$1,907 | -3.1% |
| OP Medical | \$4,812 | \$5,310 | 10.3% |
| Prescription Drug | \$2,012 | \$2,273 | 12.9% |

Overall Eligibility Trend

Annual Eligibility Trend

| Annual Engionity Tiena | | | | |
|------------------------|------------|------------|----------|--|
| | Feb 2022 – | Feb 2023 – | | |
| | Jan 2023 | Jan 2024 | % Change | |
| Members Avg | 99,754 | 100,792 | 1.0% | |
| Employees | 45,280 | 45,996 | 1.6% | |
| Spouses | 15,549 | 15,368 | -1.2% | |
| Children/Dependents | 38,925 | 39,428 | 1.3% | |
| Family Size Avg | 2.2 | 2.2 | -0.5% | |
| Member Age Avg | 34.4 | 34.4 | -0.1% | |
| Employees | 47.0 | 47.0 | -0.1% | |
| Spouses | 49.8 | 49.9 | 0.1% | |
| Children/Dependents | 13.5 | 13.5 | 0.5% | |




5


Overall Trend by Type of Service

| | Allowed Amt PMPY Med and Rx | | | Net Pay P | MPY Med and Rx | |
|---------------------|-----------------------------|------------------------|----------|------------------------|------------------------|----------|
| | Feb 2022 – Jan 2023 | Feb 2023 – Jan 2024 | % Change | Feb 2022 – Jan 2023 | Feb 2023 – Jan 2024 | % Change |
| IP Facility | \$1,707 | \$1,632 | -4.4% | \$1,635 | \$1,546 | -5.4% |
| IP Professional | \$184 | \$187 | 1.8% | \$177 | \$178 | 0.7% |
| OP Major Procedures | \$1,253 | \$1,421 | 13.4% | \$1,191 | \$1,346 | 13.0% |
| OP Radiology | \$414 | \$430 | 3.8% | \$388 | \$404 | 4.0% |
| OP Office Visits | \$591 | \$651 | 10.2% | \$505 | \$557 | 10.3% |
| OP Lab | \$314 | \$248 | -21.0% | \$285 | \$215 | -24.4% |
| OP Emergency Room | \$586 | \$651 | 11.0% | \$533 | \$590 | 10.7% |
| OP Other | \$392 | \$424 | 8.2% | \$384 | \$431 | 12.3% |
| MHSA | \$350 | \$414 | 18.2% | \$324 | \$382 | 17.8% |
| Prescription Drugs | \$2,012 | \$2,273 | 12.9% | \$1,900 | \$2,053 | 8.1% |

Allowed Amount PMPM Quarterly Trend








Cost and Use by Type of Service


| | Patients as a % of Total Members | Costs as a% of Total Allowed Amount |
|---------------------|--|--|
| IP Facility | 4.0% | 19.6% |
| IP Professional | 5.3% | 2.2% |
| OP Major Procedures | 15.8% | 17.1% |
| OP Radiology | 37.1% | 5.2% |
| OP Office Visits | 83.3% | 7.8% |
| OP Lab | 60.8% | 3.0% |
| OP Emergency Room | 16.0% | 7.8% |
| OP Other | 73.3% | 5.1% |
| MHSA | 22.0% | 5.0% |
| Prescription Drugs | 75.2% | 27.3% |






Acute Inpatient Admission Detail


| | Feb 2022 – Jan 2023 | Feb 2023 – Jan 2024 | % Change |
|---------------------------------------|------------------------|------------------------|----------|
| Medical | 17.1 | 18.2 | 6.5% |
| Maternity Surgical MHSA | 22.2 | 21.0 | -5.2% |
| हूं Surgical | 10.2 | 10.0 | -2.3% |
| F MHSA | 5.9 | 6.3 | 7.3% |
| Total | 55.3 | 55.4 | 0.3% |
| ≩ Medical | \$598 | \$644 | 7.7% |
| Medical Maternity Surgical MHSA Total | \$464 | \$399 | -14.1% |
| Surgical | \$808 | \$718 | -11.1% |
| MHSA | \$76 | \$87 | 14.3% |
| ₹ Total | \$1,947 | \$1,849 | -5.0% |
| Medical | \$574 | \$627 | 9.2% |
| ਨੂੰ Maternity | \$443 | \$377 | -14.9% |
| ੋ Surgical | \$770 | \$690 | -10.3% |
| ₹ MHSA | \$73 | \$84 | 14.6% |
| Total | \$1,860 | \$1,778 | -4.4% |






Admission PMPY Allowed Amount Trend*

| | Feb 2022 – | Feb 2023 – | |
|------------------|------------|------------|----------|
| | Jan 2023 | Jan 2024 | % Change |
| Allowed Amt PMPY | | | |
| Facility | \$1,690 | \$1,618 | -4.3% |
| Professional | \$175 | \$178 | 2.0% |
| Total | \$1,864 | \$1,796 | -3.7% |
| Net Pay PMPY | | | |
| Facility | \$1,620 | \$1,534 | -5.3% |
| Professional | \$168 | \$170 | 1.0% |
| Total | \$1,788 | \$1,704 | -4.7% |




Acute Admission Detail*

| | Feb 2022 – | Feb 2023 – | |
|-------------------|------------|------------|----------|
| | Jan 2023 | Jan 2024 | % Change |
| Length of Stay | | | |
| Medical | 6.3 | 5.5 | -12.2% |
| Surgical | 7.7 | 6.3 | -18.4% |
| Maternity | 3.3 | 3.0 | -8.0% |
| MHSA | 10.1 | 10.0 | -1.4% |
| Total | 5.7 | 5.2 | -9.3% |
| Allowed Amt/Admit | | | |
| Medical | \$35,078 | \$35,469 | 1.1% |
| Surgical | \$79,208 | \$72,080 | -9.0% |
| Maternity | \$20,941 | \$18,973 | -9.4% |
| MHSA | \$13,058 | \$13,918 | 6.6% |
| Total | \$35,224 | \$33,357 | -5.3% |
| Allowed Amt/Day | | | |
| Medical | \$5,608 | \$6,459 | 15.2% |
| Surgical | \$10,274 | \$11,457 | 11.5% |
| Maternity | \$6,416 | \$6,316 | -1.6% |
| MHSA | \$1,287 | \$1,391 | 8.1% |
| Total | \$6,141 | \$6,410 | 4.4% |



Acute Inpatient Admission Detail: Current Year Surgical Admits*




Volume

Top 10 Principal Procedures: 1,160
Total Principal Procedures: 5,588
Top 10 as a % of Total: 20.8%

Cost

Top 10 Principal Procedures (Admission Costs): \$29.0 m
Total Principal Procedures (Admission Costs): \$186.9 m
Top 10 as a % of Total Admission Costs: 15.6%



Outpatient Medical Detail

| | Allowed Amt PMPY Med | | | Patients | | | | |
|----------------------------|------------------------|------------------------|----------|------------------------|------------------------|----------|--|--|
| | Feb 2022 – Jan 2023 | Feb 2023 – Jan 2024 | % Change | Feb 2022 – Jan 2023 | Feb 2023 – Jan 2024 | % Change | | |
| Major Procedures | \$1,253 | \$1,421 | 13.4% | 17,005 | 17,858 | 5.0% | | |
| Specialty Drugs (Medical) | \$552 | \$684 | 23.8% | 3,452 | 3,655 | 5.9% | | |
| Professional Office Visits | \$591 | \$651 | 10.2% | 93,250 | 93,906 | 0.7% | | |
| Emergency Rooms | \$586 | \$651 | 11.0% | 16,840 | 18,067 | 7.3% | | |
| Radiology | \$414 | \$430 | 3.8% | 40,355 | 41,837 | 3.7% | | |
| Other Outpatient Services | \$392 | \$424 | 8.2% | 80,985 | 82,691 | 2.1% | | |
| Laboratory | \$314 | \$248 | -21.0% | 72,550 | 68,624 | -5.4% | | |
| Mental Health | \$248 | \$294 | 18.6% | 22,347 | 24,123 | 7.9% | | |
| Substance Abuse | \$22 | \$31 | 39.0% | 918 | 1,045 | 13.8% | | |
| PT, OT, Speech Therapy | \$130 | \$157 | 20.7% | 14,923 | 16,010 | 7.3% | | |
| Injections and Medications | \$84 | \$81 | -4.2% | 12,031 | 12,706 | 5.6% | | |
| Supplies and Devices | \$88 | \$98 | 11.2% | 13,435 | 14,636 | 8.9% | | |
| Dialysis | \$64 | \$66 | 3.0% | 91 | 97 | 6.6% | | |
| Durable Medical Equipment | \$34 | \$37 | 10.0% | 4,432 | 4,716 | 6.4% | | |

© 2024 Merative


13

Outpatient Medical Detail

| | Utilization | n (Services per 100 | 0) | Price (Allowed Ar | nount per Service) | |
|----------------------------|------------------------|------------------------|----------|------------------------|------------------------|----------|
| | Feb 2022 – Jan 2023 | Feb 2023 – Jan 2024 | % Change | Feb 2022 – Jan 2023 | Feb 2023 – Jan 2024 | % Change |
| Major Procedures | 1,879.4 | 1,987.2 | 5.7% | \$667 | \$715 | 7.2% |
| Specialty Drugs (Medical) | 279.8 | 303.8 | 8.6% | \$1,974 | \$2,252 | 14.0% |
| Professional Office Visits | 5,577.3 | 5,688.2 | 2.0% | \$106 | \$115 | 8.1% |
| Emergency Rooms | 2,044.3 | 2,121.1 | 3.8% | \$287 | \$307 | 6.9% |
| Radiology | 1,727.8 | 1,762.6 | 2.0% | \$240 | \$244 | 1.8% |
| Other Outpatient Services | 3,413.8 | 3,618.9 | 6.0% | \$115 | \$117 | 2.1% |
| Laboratory | 7,671.9 | 7,156.7 | -6.7% | \$41 | \$35 | -15.3% |
| Mental Health | 2,489.7 | 2,737.4 | 10.0% | \$99 | \$107 | 7.9% |
| Substance Abuse | 175.3 | 222.4 | 26.9% | \$128 | \$140 | 9.5% |
| PT, OT, Speech Therapy | 4,118.3 | 4,395.7 | 6.7% | \$32 | \$36 | 13.0% |
| Injections and Medications | 781.8 | 816.8 | 4.5% | \$108 | \$99 | -8.3% |
| Supplies and Devices | 1,094.8 | 1,218.3 | 11.3% | \$80 | \$80 | -0.1% |
| Dialysis | 105.1 | 108.8 | 3.5% | \$612 | \$609 | -0.5% |
| Durable Medical Equipment | 182.3 | 222.7 | 22.2% | \$185 | \$166 | -9.9% |

Outpatient Medical Detail: Professional Office Visits


| | | % Visits | | % A | llowed Amt | | Allowe | ed Amount/V | 'isit | Vi | sits per 1000 | |
|-----------------------|------------|------------|--------|------------|------------|--------|------------|-------------|--------|------------|---------------|----------|
| | Feb 2022 - | Feb 2023 - | | Feb 2022 – | Feb 2023 - | | Feb 2022 - | Feb 2023 - | % | Feb 2022 – | Feb 2023 - | |
| | Jan 2023 | Jan 2024 | Change | Jan 2023 | Jan 2024 | Change | Jan 2023 | Jan 2024 | Change | Jan 2023 | Jan 2024 | % Change |
| Specialist Visits | 37.0% | 35.8% | -1.2% | 36.2% | 34.7% | -1.5% | \$122 | \$130 | 6.8% | 1,515 | 1,501 | -0.9% |
| Non-Specialist Visits | 63.0% | 64.2% | 1.2% | 63.8% | 65.3% | 1.5% | \$126 | \$136 | 8.3% | 2,583 | 2,698 | 4.5% |
| Total | 100.0% | 100.0% | | 100.0% | 100.0% | | \$124 | \$134 | 7.8% | 4,098 | 4,200 | 2.5% |




| Total All Specialists | 1,501 | \$130 |
|-------------------------------|------------|----------------|
| All Other Specialists | 342 | \$152 |
| Top 15 | 1,164 | \$123 |
| Oncology | 40 | \$152 |
| Allergy & Immunology | 40 | \$153 |
| Endocrinology & Metabolism | 42 | \$139 |
| Neurology | 39 | \$162 |
| Surgeon (NEC) | 39 | \$136 |
| Pain Mgmt/Pain Medicine | 52 | \$115 |
| Otolaryngology | 53 | \$153 |
| Urology | 52 | \$119 |
| Ophthalmology | 55 | \$114 |
| Chiropractor/DCM | 64 | \$84 |
| Emergency Medicine | 67 | \$175 |
| Podiatry | 112 | \$92 |
| Cardiovascular Dis/Cardiology | 115 | \$129 |
| Orthopaedic Surgery | 190 | \$129 |
| Dermatology | 208 | \$96 |
| | 1000 | Per Visit |
| | Visits per | Allowed Amount |

Outpatient Medical Detail: Radiology


| | Se | rvices per 100 | 0 | Allowed | d Amount per S | Service | Allow | ed Amount P | MPY | N | Net Pay PMPY | |
|------------------|------------|----------------|----------|------------|----------------|----------|------------|-------------|----------|------------|--------------|----------|
| Outpatient | | | | | | | | | | | | |
| Radiology | Feb 2022 - | Feb 2023 - | | Feb 2022 - | Feb 2023 - | | Feb 2022 - | Feb 2023 - | | Feb 2022 - | Feb 2023 - | |
| Services | Jan 2023 | Jan 2024 | % Change | Jan 2023 | Jan 2024 | % Change | Jan 2023 | Jan 2024 | % Change | Jan 2023 | Jan 2024 | % Change |
| CAT Scans | 87.7 | 96.6 | 10.2% | \$435 | \$429 | -1.4% | \$38 | \$41 | 8.7% | \$35 | \$37 | 6.1% |
| MRIs | 113.0 | 119.5 | 5.8% | \$554 | \$556 | 0.4% | \$63 | \$66 | 6.2% | \$58 | \$62 | 7.2% |
| Mammograms | 420.6 | 445.1 | 5.8% | \$119 | \$121 | 1.7% | \$50 | \$54 | 7.6% | \$49 | \$53 | 8.0% |
| PET Scans | 5.3 | 7.3 | 37.2% | \$3,003 | \$2,799 | -6.8% | \$16 | \$20 | 27.9% | \$15 | \$20 | 27.9% |
| Nuclear Medicine | 28.3 | 31.0 | 9.4% | \$727 | \$763 | 5.0% | \$21 | \$24 | 14.9% | \$20 | \$23 | 14.1% |
| Therapeutic | 108.3 | 95.7 | -11.7% | \$1,065 | \$1,141 | 7.1% | \$115 | \$109 | -5.4% | \$113 | \$109 | -4.3% |
| Ultrasounds | 428.5 | 413.1 | -3.6% | \$166 | \$173 | 4.0% | \$71 | \$71 | 0.2% | \$64 | \$65 | 0.1% |
| X-Rays | 504.6 | 520.9 | 3.2% | \$73 | \$76 | 4.1% | \$37 | \$39 | 7.5% | \$31 | \$33 | 7.8% |
| Other | 31.5 | 33.5 | 6.3% | \$104 | \$120 | 15.2% | \$3 | \$4 | 22.4% | \$3 | \$4 | 22.1% |
| Total | 1727.8 | 1762.6 | 2.0% | \$240 | \$244 | 1.8% | \$414 | \$430 | 3.8% | \$388 | \$404 | 4.0% |






Outpatient Medical Detail: Laboratory

| | Se | rvices per 100 | 0 | Allowed | l Amount per S | Service | Allow | ed Amount Pl | MPY | 1 | Net Pay PMPY | |
|-----------------|------------|----------------|----------|------------|----------------|----------|------------|--------------|----------|------------|--------------|----------|
| Outpatient Lab | Feb 2022 - | Feb 2023 - | | Feb 2022 - | Feb 2023 - | | Feb 2022 - | Feb 2023 - | | Feb 2022 - | Feb 2023 - | |
| Services | Jan 2023 | Jan 2024 | % Change | Jan 2023 | Jan 2024 | % Change | Jan 2023 | Jan 2024 | % Change | Jan 2023 | Jan 2024 | % Change |
| Chemistry Tests | 3621.8 | 3873.7 | 7.0% | \$20 | \$21 | 5.6% | \$73 | \$82 | 12.9% | \$59 | \$64 | 9.6% |
| Hematology | 566.1 | 588.6 | 4.0% | \$15 | \$16 | 0.5% | \$9 | \$9 | 4.5% | \$6 | \$7 | 10.1% |
| Immunology | 856.2 | 553.2 | -35.4% | \$30 | \$27 | -9.1% | \$25 | \$15 | -41.3% | \$24 | \$13 | -45.1% |
| Microbiology | 1649.6 | 1174.8 | -28.8% | \$73 | \$44 | -40.7% | \$121 | \$51 | -57.7% | \$117 | \$46 | -60.5% |
| Pathology | 459.1 | 451.1 | -1.7% | \$132 | \$139 | 5.6% | \$60 | \$63 | 3.8% | \$56 | \$58 | 4.8% |
| Urinalysis | 312.8 | 321.2 | 2.7% | \$5 | \$5 | 3.1% | \$2 | \$2 | 5.9% | \$1 | \$1 | 7.7% |
| Other | 206.1 | 194.1 | -5.8% | \$117 | \$136 | 16.3% | \$24 | \$26 | 9.6% | \$22 | \$25 | 13.0% |
| Total | 7671.9 | 7156.7 | -6.7% | \$41 | \$35 | -15.3% | \$314 | \$248 | -21.0% | \$285 | \$215 | -24.4% |







Prescription Drug Detail*

Annual Trend

| | | Feb 2022 - | Feb 2023 - | |
|-----------------|-------------------------------|------------|------------|----------|
| | | Jan 2023 | Jan 2024 | % Change |
| Total | Allowed Amount PMPY | \$2,012 | \$2,273 | 12.9% |
| 2 | Net Pay PMPY | \$1,900 | \$2,053 | 8.1% |
| | Out of Pocket PMPY | \$106 | \$113 | 6.5% |
| | Patients per 1000 | 776.8 | 751.8 | -3.2% |
| | Allowed Amount per Day Supply | \$4.35 | \$4.83 | 11.0% |
| _ | Days Supply PMPY | 462.3 | 470.4 | 1.7% |
| Mail Order | Allowed Amount PMPY | \$102 | \$134 | 31.3% |
| Ö | Net Pay PMPY | \$96 | \$126 | 31.4% |
| ail | Out of Pocket PMPY | \$6 | \$7 | 15.4% |
| Σ | Patients per 1000 | 45.5 | 44.8 | -1.5% |
| | Allowed Amount per Day Supply | \$2.51 | . \$3.49 | 39.5% |
| | Days Supply PMPY | 40.8 | 38.4 | -5.8% |
| Retail | Allowed Amount PMPY | \$962 | \$1,049 | 9.0% |
| Re | Net Pay PMPY | \$866 | \$944 | 9.1% |
| | Out of Pocket PMPY | \$92 | \$98 | 6.9% |
| | Patients per 1000 | 772.8 | 747.1 | -3.3% |
| | Allowed Amount per Day Supply | \$2.33 | \$2.48 | 6.5% |
| _ | Days Supply PMPY | 413.7 | 423.4 | 2.4% |
| Specialty | Allowed Amount PMPY | \$948 | \$1,090 | 15.0% |
| ecia | Net Pay PMPY | \$938 | \$ \$983 | 4.7% |
| Spe | Out of Pocket PMPY | \$8 | \$ \$7 | -5.9% |
| | Patients per 1000 | 36.8 | 38.5 | 4.6% |
| | Allowed Amount per Day Supply | \$120.68 | \$127.53 | 5.7% |
| © 2024 Merative | Days Supply PMPY | 7.9 | 8.5 | 8.8% |






^{*}Specialty drugs on this slide includes drugs covered under the prescription drug benefit and excludes drugs covered under the medical plans.

Prescription Drug Detail: Non-Specialty Drugs

Annual Trend

| | Allowe | ed Amount | PMPY | N | et Pay PMP | Υ | Allowed | Amt per Da | ys Supply | Day | s Supply PN | MPY | Ger | neric Efficie | ncy |
|----------------------------|------------|------------|----------|------------|------------|----------|------------|------------|-----------|------------|-------------|----------|------------|---------------|----------|
| | Feb 2022 - | Feb 2023 - | | Feb 2022 - | Feb 2023 - | | Feb 2022 - | Feb 2023 - | | Feb 2022 - | Feb 2023 - | | Feb 2022 - | Feb 2023 - | |
| Therapeutic Class | Jan 2023 | Jan 2024 | % Change | Jan 2023 | Jan 2024 | % Change | Jan 2023 | Jan 2024 | % Change | Jan 2023 | Jan 2024 | % Change | Jan 2023 | Jan 2024 | % Change |
| Hormones & Synthetic Subst | \$465 | \$581 | 24.9% | \$440 | \$553 | 25.7% | \$6 | \$7 | 21.1% | 81 | 83 | 3.2% | 93.5% | 93.5% | 0.0% |
| Central Nervous System | \$249 | \$225 | -9.4% | \$221 | \$197 | -10.9% | \$2 | \$2 | -11.7% | 113 | 116 | 2.6% | 95.0% | 98.7% | 3.9% |
| Cardiovascular Agents | \$50 | \$54 | 8.7% | \$36 | \$42 | 14.1% | \$0 | \$0 | 7.5% | 119 | 121 | 1.1% | 99.9% | 100.0% | 0.0% |
| Blood Form/Coagul Agents | \$46 | \$49 | 6.3% | \$44 | \$47 | 6.1% | \$8 | \$9 | 2.6% | 6 | 6 | 3.6% | 100.0% | 99.8% | -0.2% |
| Gastrointestinal Drugs | \$41 | \$38 | -5.2% | \$36 | \$34 | -5.6% | \$2 | \$2 | -8.8% | 24 | 25 | 4.0% | 99.9% | 99.9% | 0.0% |
| Serums, Toxoids, Vaccines | \$27 | \$36 | 34.2% | \$27 | \$36 | 34.3% | \$50 | \$106 | 111.4% | 1 | 0 | -36.5% | 100.0% | 100.0% | 0.0% |
| Autonomic Drugs | \$34 | \$31 | -8.9% | \$30 | \$26 | -11.1% | \$3 | \$2 | -10.9% | 12 | 12 | 2.4% | 99.9% | 99.9% | 0.0% |
| Diagnostic Agents | \$29 | \$28 | -4.9% | \$25 | \$22 | -12.6% | \$3 | \$3 | 6.1% | 9 | 8 | -10.4% | 0.0% | 0.0% | 0.0% |
| Eye, Ear, Nose Throat | \$26 | \$27 | 1.9% | \$22 | \$22 | -0.2% | \$2 | \$3 | 40.4% | 14 | 10 | -27.4% | 98.6% | 97.7% | -0.9% |
| Skin & Mucous Membrane | \$28 | \$26 | -7.4% | \$25 | \$22 | -10.3% | \$3 | \$3 | -15.6% | 9 | 10 | 9.7% | 98.7% | 98.7% | 0.0% |
| All Other Values | \$69 | \$87 | 25.2% | \$55 | \$68 | 24.5% | \$1 | \$1 | 19.7% | 67 | 70 | 4.6% | 99.8% | 99.8% | 0.0% |
| Total | \$1,065 | \$1,183 | 11.1% | \$961 | \$1,070 | 11.3% | \$2 | \$3 | 9.4% | 454 | 462 | 1.6% | 97.6% | 98.7% | 1.1% |



Specialty Drug Detail¹

| | Allowed Amount | | | Patients | | | Allowed Amount per Patient | | | |
|------------------------|------------------------|------------------------|----------|------------------------|------------------------|----------|----------------------------|------------------------|----------|--|
| | Feb 2022 – Jan 2023 | Feb 2023 – Jan 2024 | % Change | Feb 2022 – Jan 2023 | Feb 2023 – Jan 2024 | % Change | Feb 2022 – Jan 2023 | Feb 2023 – Jan 2024 | % Change | |
| Medical Specialty | \$55,126,365 | \$68,963,819 | | | 3,655 | 5.8% | _ | \$18,868 | 18.2% | |
| Prescription Specialty | \$94,563,126 | \$109,864,934 | 16.2% | 4,090 | 4,344 | 6.2% | \$23,121 | \$25,291 | 9.4% | |

| | Top 10 Specialty Drugs Through Medical Plans | Allowed Amount | Patients Al | llowed/Patient |
|------------------|--|----------------|-------------|----------------|
| J9271 | Inject pembrolizumab 1 mg | \$8,051,465 | 60 | \$134,191 |
| J2350 | Inject, ocrelizumab, 1 mg | \$3,667,763 | 52 | \$70,534 |
| J2506 | Inject, pegfilgrastim, excl biosimilar, 0.5 mg | \$3,134,889 | 59 | \$53,134 |
| J9144 | Inj, daratumumab, 10 mg and hyaluronidase-fihj | \$3,095,641 | 16 | \$193,478 |
| J9299 | Inject nivolumab 1 mg | \$2,331,531 | 20 | \$116,577 |
| J3380 | Inject vedolizumab 1 mg | \$2,087,095 | 51 | \$40,923 |
| 96413 | CHEMOTX ADMN IV NFS TQ UP 1 HR | \$1,749,584 | 555 | \$3,152 |
| J2323 | Injection natalizumab, 1 mg | \$1,373,175 | 13 | \$105,629 |
| J0585 | Injection onabotulinumtoxinA, 1 unit | \$1,308,072 | 312 | \$4,193 |
| Q5103 | Inj, infliximab-dyyb, inflectra, 10 mg | \$1,183,047 | 78 | \$15,167 |
| Total Top | 10 | \$8,051,465 | 60 | \$134,191 |
| Percent o | f Overall Total (Medical Specialty) | 38.9% | 31.1% | |

¹Specialty drugs are defined in a Merative service category group and include drugs paid under the prescription benefit and the medical benefit. Although there is no consensus definition, the continuum of drugs included may have the following characteristics: relatively costly (at least \$670 per month for a 30-day supply, according to CMS); often injected or infused; involve a significant degree of patient education, monitoring and management; require special preparation, handling or monitoring; and may be biologically created vs. a chemical compound.

Specialty Drug Detail

| Top 15 | Through | the | Prescri | iption | Plan |
|---------------|---------|-----|---------|--------|------|
|---------------|---------|-----|---------|--------|------|

| | Allowed Amount | Patients |
|---|----------------|----------|
| HUMIRA | \$13,763,677 | 222 |
| STELARA | \$7,237,440 | 79 |
| DUPIXENT | \$6,358,861 | 263 |
| TREMFYA | \$5,901,533 | 105 |
| SKYRIZI | \$4,637,478 | 85 |
| ENBREL | \$2,812,892 | 62 |
| COSENTYX | \$2,541,333 | 51 |
| TALTZ | \$2,220,014 | 45 |
| OTEZLA | \$1,885,761 | 65 |
| TRIKAFTA | \$1,879,508 | 7 |
| VERZENIO | \$1,856,813 | 15 |
| BIKTARVY | \$1,827,316 | 60 |
| SPRYCEL | \$1,624,980 | 13 |
| RINVOQ | \$1,604,240 | 45 |
| CIMZIA | \$1,481,203 | 30 |
| Total Top 15 | \$57,633,049 | 1,147 |
| Percent of Overall Total (Rx Specialty) | 52.5% | 26.4% |


Mental Health and Substance Abuse Detail


| | . IV | lental Health | | Substance Abuse | | | |
|-----------------------------|------------|---------------|----------|-----------------|------------|----------|--|
| | Feb 2022 – | Feb 2023 – | | Feb 2022 – | Feb 2023 – | | |
| | Jan 2023 | Jan 2024 | % Change | Jan 2023 | Jan 2024 | % Change | |
| Overall | | | | | | | |
| Patients per 1000 Inpatient | 4.2 | 4.3 | 2.7% | 1.4 | 1.4 | 1.0% | |
| Pats per 1000 Outpatient | 201.1 | 213.9 | 6.3% | 8.3 | 9.3 | 12.1% | |
| Inpatient | | | | | | | |
| Allow Amt PMPY Adm Acute | \$51 | \$62 | 21.2% | \$25 | \$25 | 0.5% | |
| Net Pay PMPY Adm Acute | \$49 | \$60 | 21.9% | \$24 | \$24 | -0.3% | |
| Allow Amt Per Adm Acute | \$13,099 | \$15,071 | 15.1% | \$12,975 | \$11,725 | -9.6% | |
| Days LOS Admit Acute | 10.3 | 10.2 | -0.8% | 9.9 | 9.6 | -2.4% | |
| Admits Per 1000 Acute | 3.9 | 4.1 | 5.3% | 1.9 | 2.2 | 11.2% | |
| Outpatient | | | | | | | |
| Allow Amt PMPY OP Med | \$241 | \$289 | 19.9% | \$22 | \$31 | -16.9% | |
| Net Pay PMPY OP Med | \$221 | \$263 | 19.2% | \$20 | \$29 | -17.2% | |
| Allow Amt Per Svc OP Med | \$100 | \$109 | 9.3% | \$126 | \$140 | 3.2% | |
| Svcs Per 1000 OP Med | 2407.3 | 2642.0 | 9.7% | 174.6 | 221.5 | -19.5% | |

© 2024 Merative

22

Preventive Visits and Screening Overview





© 2024 Merative


23


Clinical Overview

| Annual Trend: Conditions of Interest | Allowed Amount PMPY (Medical) | | Patients per 1000 | | | Allowed Amount per Patient (Medical) | | | |
|--------------------------------------|-------------------------------|------------|-------------------|------------|------------|--------------------------------------|-----------------------|-------------|--------|
| | Feb 2022 – | Feb 2023 – | | Feb 2022 – | Feb 2023 – | | Feb 2022 – Feb 2023 – | | |
| | Jan 2023 | Jan 2024 | Change | Jan 2023 | Jan 2024 | Change | Jan 2023 | Jan 2024 | Change |
| Asthma | \$27.51 | \$28.23 | 2.6% | 36.1 | 37.9 | 4.8% | \$683.93 | \$666.63 | -2.5% |
| Cancer - Breast | \$95.16 | \$142.84 | 50.1% | 7.0 | 7.2 | 3.2% | \$12,219.87 | \$17,692.52 | 44.8% |
| Cancer - Colon | \$20.81 | \$33.58 | 61.4% | 1.6 | 1.6 | 4.1% | \$11,796.10 | \$18,199.70 | 54.3% |
| Cancer - Lung | \$34.28 | \$35.33 | 3.0% | 1.1 | 1.1 | 0.1% | \$27,367.70 | \$28,045.03 | 2.5% |
| Cancer - Skin | \$26.34 | \$33.13 | 25.8% | 27.9 | 28.8 | 3.4% | \$849.05 | \$1,027.42 | 21.0% |
| Cerebrovascular Disease | \$76.04 | \$82.90 | 9.0% | 11.2 | 11.5 | 3.4% | \$6,123.89 | \$6,424.87 | 4.9% |
| Chronic Obstruc Pulm Dis(COPD) | \$10.59 | \$12.06 | 13.9% | 5.2 | 5.6 | 7.3% | \$1,815.21 | \$1,918.37 | 5.7% |
| Congestive Heart Failure | \$19.41 | \$14.36 | -26.0% | 2.9 | 3.3 | 11.2% | \$5,959.77 | \$3,945.13 | -33.8% |
| Coronary Artery Disease | \$105.71 | \$113.74 | 7.6% | 14.1 | 14.6 | 4.0% | \$6,744.06 | \$6,945.65 | 3.0% |
| Diabetes | \$100.30 | \$105.20 | 4.9% | 90.8 | 99.3 | 9.3% | \$991.80 | \$947.23 | -4.5% |
| Hypertension, Essential | \$70.10 | \$85.13 | 21.4% | 118.3 | 117.2 | -0.9% | \$532.25 | \$649.18 | 22.0% |
| Mental Hlth - Depression | \$113.40 | \$136.56 | 20.4% | 92.8 | 98.0 | 5.5% | \$1,096.95 | \$1,246.17 | 13.6% |
| Osteoarthritis | \$179.12 | \$197.73 | 10.4% | 61.8 | 62.0 | 0.3% | \$2,603.78 | \$2,852.08 | 9.5% |
| Renal Function Failure | \$99.84 | \$110.12 | 10.3% | 10.3 | 11.4 | 10.0% | \$8,677.66 | \$8,660.39 | -0.2% |
| Spinal/Back Disord, Low Back | \$190.35 | \$170.12 | -10.6% | 95.0 | 96.6 | 1.7% | \$1,799.63 | \$1,574.73 | -12.5% |
| Pneumonia | \$20.85 | \$33.24 | 59.4% | 6.8 | 8.7 | 27.7% | \$2,752.35 | \$3,419.27 | 24.2% |
| Pregnancy | \$308.22 | \$303.31 | -1.6% | 25.1 | 25.0 | -0.6% | \$11,027.03 | \$10,867.52 | -1.4% |

Risk Profile¹ (Based on FY23 Claims Experience)

| | Member Age Avg | Allowed Amount | Allow Amt PMPY | Patients |
|------------|----------------|----------------|----------------|----------|
| Healthy | 25.1 | \$21,306,114 | \$702 | 27,410 |
| Stable | 29.8 | \$63,994,131 | \$2,624 | 25,936 |
| At Risk | 39.8 | \$162,793,182 | \$6,605 | 26,519 |
| Struggling | 46.1 | \$331,567,653 | \$19,273 | 18,487 |
| In Crisis | 50.8 | \$303,273,429 | \$88,302 | 3,896 |





Risk Categories

- **Healthy** represents nearly 50% of the privately insured under-65 U.S. population, who account for less than 5% of total healthcare cost. Most patients in this category are infrequent or non-utilizers of the healthcare system, most often being treated for occasional low severity acute conditions.
- **Stable** represents nearly 25% of the privately insured under-65 U.S. population, who account for 10-15% of total healthcare cost. Most patients in this category are somewhat active utilizers of the healthcare system, most often being treated for low-severity acute conditions.
- At Risk represents between 15 and 20% of the privately insured under-65 U.S. population, who account for 20-25% of total healthcare cost. Most patients in this category are active utilizers of the healthcare system, most often being treated for multiple medium-severity acute conditions and/or low-severity chronic conditions.
- **Struggling** represents between 5 and 10% of the privately insured under-65 U.S. population, who account for 25-30% of total healthcare cost. Most patients in this category are heavy utilizers of the healthcare system, most often being treated for multiple high-severity acute conditions and/or medium-severity chronic conditions.
- In-Crisis represents the top 2% of the privately insured under-65 U.S. population, who account for approximately 30% of total healthcare cost. Most patients in this category are heavy utilizers of the healthcare system, most often being treated for multiple severe acute and/or chronic conditions.